allogeneic hematopoietic stem cells (National Institutes of Health)

This refers to a specific cell therapy protocol developed by the National Institutes of Health Clinical Center (CC) for the treatment of various hematologic malignancies. The therapy involves the transplantation of T-cell depleted allogeneic hematopoietic stem cells derived from haploidentical related donors. The protocol utilizes reduced-intensity conditioning (RIC) to minimize treatment-related toxicity while facilitating donor cell engraftment. By depleting T-cells from the donor graft, the approach aims to reduce the incidence and severity of graft-versus-host disease (GVHD), a significant risk in haploidentical transplantation, while preserving a graft-versus-tumor (GVT) effect to eliminate residual malignant cells. This therapeutic strategy is primarily investigated for patients with high-risk leukemias, lymphomas, and multiple myeloma who lack a fully HLA-matched donor.

Other names

T-cell depleted haploidentical allogeneic hematopoietic stem cellshaploidentical peripheral blood stem cellsallogeneic peripheral blood stem cell transplantation